Publications by Epividian Scientists and Collaborators

 

Abstracts and Posters


Henegar C, Beckerman R, Fusco J. The impact of HIV coinfection on hepatitis c virus (HCV) treatment initiation. International Conference on Pharmacoepidemiology. August 26-30, 2017, Montreal, Canada.

Mounzer K, Hsu R, Henegar C, Fusco J, Vannappagari V, Stainsby C, Shaefer M, Fusco G. Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA abservational database. Abstract A-854-0101-04667. International AIDS Society. July 23-26, 2017, Paris, France.

Carpio F, Henegar C, Fusco J, Byrd Quinlivan E, Vannappagari V, Aboud M, Smith K, Fusco G. Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA observational database. Abstract A-854-0129-02932. International AIDS Society. July 23-26, 2017, Paris, France.

Hsu R, Fusco J, Henegar C, Carpio F, Mounzer K, Wohlfeiler M, Vannappagari V, Aboud M, Curtis L, Fusco G. Psychiatric disorders observed in HIV+ patients using 6 common 3rd agents in OPERA. Poster 664. Conference on Retroviruses and Opportunistic Infections. February 13-16, 2017, Seattle, WA. Download PDF >

Dieterich D, Henegar C, Fusco J, Lackey P. Hepatitis C virus testing, prevalence, and treatment in a large cohort of treatment-naïve, HIV-positive individuals. AASLD The Liver Meeting. November 6-11, 2016, Boston, MA. Download PDF >

Melikian G, Lackey P, Henegar C, Zelt S, Fusco J, Schulman K, D’Amico R, Wohlfeiler M. Syphilis, race, baseline labs, and antiretroviral regimen predict virologic success in naïve HIV+ adolescents and young adults. Poster 1541. Infectious Diseases Week. October 26-30, 2016, New Orleans, LA. Download PDF >

Mills A, Fusco J, Schulman K, Henegar C, Zelt S, D’Amico R, Carpio F. The impact of antiretroviral tablet burden and polypharmacy on viral suppression in treatment-naïve patients. Poster 1512. Infectious Diseases Week. October 26-30, 2016, New Orleans, LA. Download PDF >

Melikian G, Fusco J, Schulman K, Henegar C, Zelt S, D’Amico R, Lackey P. Variability in population characteristics among HIV+ ART-naïve patients initiating on single tablet regimens. Poster 1517. Infectious Diseases Week. October 26-30, 2016, New Orleans, LA. Download PDF >

Wohlfeiler M, Henegar C, Schulman K, Fusco J, Zelt S, D’Amico R, Melikian G. Predictors of virologic success in an older ART naïve HIV population. Poster 2127. Infectious Diseases Week. October 26-30, 2016, New Orleans, LA. Download PDF >

Dieterich D, Fusco J, Henegar C, D’Amico R, Schulman K, Zelt S, Lackey P. HIV/Hepatitis C co-infected patients are significantly more complex to manage than HIV mono-infected patients in a large cohort of treatment-naïve, HIV-positive individuals. Poster P260. HIV Drug Therapy Glasgow Meeting, October 23-26, 2016, Glasgow, UK. Download PDF >

Lackey P, Schulman K, Henegar C, D’Amico R, Zelt S, Fusco J. Trends in HIV antiretroviral tablet burden in treatment-naïve patients in the United States. The Academy of Managed Care Pharmacy (AMCP) Nexus Meeting 2016, October 3-6, 2016, National Harbor, MD. Silver Award Recipient. Download PDF >

Wohlfeiler M, Carpio F, Lackey P, Henegar C, Fusco J, Jonsson Funk M, Vonesh E, DeJesus E, Fusco G, Mills A. INSTI In-Class Switching on Continued Viral Suppression in the OPERA Cohort. Poster 953. Conference on Retroviruses and Opportunistic Infections. February 22-25, 2016, Boston, MA. Download PDF >

Lackey P, Mills A, Carpio F, Hsu R, DeJesus E, Pierone G, Henegar C, Brouwer E, Fusco J, Fusco G, Wohlfeiler M. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Poster 1086. Infectious Diseases Week. October 7-11, 2015, San Diego, CA Download PDF >

DeJesus E, Pierone G, Lackey P, Wohlfeiler M, Carpio F, Fusco J, Fusco G, Dieterich D. Utilization patterns of raltegravir within the OPERA database. Poster P277. 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), October-November 2009, Philadelphia, PA. Download PDF >

SL Becker, RB Balu, JS Fusco, and GP Fusco. Beyond serum creatinine: Identification of renal insufficiency using GFR: Implications for clinical research and care. Poster. Conference on Retroviruses and Opportunistic Infections, February 2005, Boston, MA.

Fultz SL, Chang CCH, Skanderson M, Butt AA, Rigsby MO, Fusco GP, Dieterich DT, Becker SL, Simberkoff M, Rabeneck L, Rodriguez-Barradas M, Justice AC. Survival in patients coinfected with HIV and Hepatitis C: Is there a CD4 threshold. Poster. XV International AIDS Conference, July 2004, Bangkok, Thailand.

Mera R, Most B, Balu RB, Fusco JS. Dynamics of immunologic decline and virological rebound during treatment interruption in chronic HIV disease. 4593. Poster. XV International Aids Conference, July 2004, Bangkok, Thailand.

Gibbons DC, Baker RK, Bartlett JA, Cutrell AG, Eron JJ, Fusco GP, Fusco JS, Gallant JE, Mole L, Moore RD, Nordstrom BL, Rosenberg DM, Walker AM, White AD, Wood KC. Use of novel methodology for a risk management program examining risk of abacavir hypersensitivity reaction, rechallenge reaction, hospitalization, and death. Poster. 19th International Conference on Pharmacoepidemiology and the 1st International Conference on Therapeutic Risk Management. August 2003, Philadelphia, PA.

Raffanti SR, Fusco JS, Becker SL, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Moderate viremia and HIV disease progression. Poster. LB35, International AIDS Society Conference. July 2003, Paris, France.

Balu RB, Raffanti s, Wesolowski L, Justice AC, Fusco JS, Mangialardi W, Fusco GP. Sex specific differences in liver function and disease progression. Poster. 7th International Workshop on HIV Databases. March 2003, Fiuggi, Italy.

Paulsen D, Florance A, Liao Q, Boulme R, Shaefer M, Fusco GP, Ross L. Comparison of HIV-1 protease inhibitor susceptibility results in viremic protease inhibitor(PI)-experienced patient samples analyzed by phenotyping and by five resistance algorithms. Poster. 6th International HIV Drug Resistance Workshop. July 2002, Seville, Spain.

Chene C, May M, Costagliola D, d’Arminio Monforte A, Junghans C, de Wolf F, Lundgren JD, Fusco GP, Miller V, Leport C, Dabis F, Hogg RS, Phillips AN, Gill MJ, Salzberger B, Sterne JAC, Egger M. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain.

Dieterich DT, Becker SL, Fusco JS, Balu RB, Most BM, Stern JAC, Lanes S, Fusco GP. Low incidence of grade III/IV hepatotoxicity in first HAART: observations from 1100 patients followed for 1 year. Poster. 4534. XIV International AIDS Conference. July 2002, Barcelona, Spain.

Fusco GP, Justice AC, Becker SL, Raffanti SP, Coll-Erickson P, Fusco JS. Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study. Poster. 5584. XIV International AIDS Conference. July 2002, Barcelona, Spain.

Sterne JAS, Grabar S, d'Arminio Monforte A, Rickenbach M, de Wolf F, Lundgren JD, Fusco JS, Miller V, Raffi F, Dabis F, Hogg RS, Lampe F, Gill MJ, Salzberger B, May M, Egger M. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART cohort collaboration. Poster. XIV International AIDS Conference. July 2002, Barcelona, Spain.

Ross L, Paulsen D, Liao Q, Fusco GP, Shaefer M, St. Clair M. Genotypic and phenotypic resistance patterns to Lopinavir and Amprenavir in viremic protease inhibitor-experienced patients. Poster. 4th International HIV Workshop on Management of Treatment-Experienced Patients. April 2001, Chicago, IL.

Becker SL, Scarsella AJ, Chulay J, Fusco GP. Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experience patients. Poster. 39th Annual Meeting of the Infectious Disease Society of America (IDSA). October 2001, San Francisco, CA.

Becker SL, Dieterich DT, Fusco GP. Clinical experience of lopinavir / ritonavir (LPV/RTV) following amprenavir (APV) use. Poster. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. October 2001, Athens, Greece.

Braun JF, Fusco JS, Justice AC, Most BM, Fusco GP. Predictors of virologic and immunologic success post treatment interruption (TI) in patients with chronic HIV infection. Poster. 1909. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 15-19, 2001, Chicago, IL.

Becker SL, Fusco JS, Justice AC, Hansen NI, Fusco GP. Comparison of protease inhibitor (PI)-containing and non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing HAART in HIV patients naïve to antiretrovirals. Poster 230. International AIDS Society Conference on HIV Pathogenesis and Treatment. July 8 –11, 2001, Buenos Aires, Argentina.

Paulsen D, Shaefer M, Fusco GP, Ross L. Cross-resistance to amprenavir and lopinavir in HIV-1 from subjects failing protease inhibitor therapies; mutations in HIV-1 with resistance to one or both drugs. Poster. 5th International Workshop on HIV Drug Resistance & Treatment Strategies. June 4-8, 2001, Scottsdale, AZ.

Justice AC, Fusco JS, Becker SL, Raffanti SR, Fusco GP. Strategies for obtaining consistent diagnoses for cause of death in an observational cohort study. Poster. 5th International Workshop on HIV Observational Databases. April 2001, Monte Carlo, Monaco.

Scarsella AJ, Dieterich DT, Graham NMH, Fusco GP, Sherrill BH, Fusco JS, Hansen NI, Becker SL. Predictors of lipodystrophy in HIV-infected patients. Poster. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2000, Toronto, Ontario.

Becker SL, Scarsella A, Graham N, Fusco GP, Sherrill B, Fusco JS, Hansen N. Efficacy of amprenavir-containing HAART regimens in protease inhibitor-experienced patients. Poster. 38th Annual Meeting of the Infectious Disease Society of America (IDSA). September 2000, New Orleans, LA.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Danehower SC, Fusco JS, Hansen NI, Becker SL. Comparative effects on clinical progression of d4T vs. ZDV containing regimens. Poster. 7th Conference on Retroviruses and Opportunistic Infections. January-February 2000, San Francisco, CA.

Justice A, Stein DS, Fusco GP, Sherrill B, Danehower S, Fusco J, Hansen N, Becker S. Relationships among antiretroviral therapies (ART) and clinical outcomes. Poster. 7th Conference on Retroviruses and Opportunistic Infections. January-February 2000, San Francisco, CA.

Raffanti SR, Fusco GP, Mangialardi WJ, Fusco JS, Hansen NI, Sherrill BH, Igboko EF. The effect of virologic control on rates of disease progression. Poster. 37th Annual Meeting of the Infectious Disease Society of America (IDSA). November 1999, Philadelphia, PA.